The current pandemic caused by the coronavirus disease 2019 (COVID-19) continues affecting millions of people worldwide. Various cardiovascular manifestations have been associated with COVID-19 but only a few case reports of Brugada syndrome in severe acute respiratory syndrome coronavirus-2 were published. The diagnosis, prognosis, and treatment remain a challenge and represent a concern in terms of management in this population. We describe a case of a 66-year-old patient with COVID-19 presenting a coved type-1 Brugada pattern in electrocardiogram. Drug challenge was performed for the diagnosis of Brugada syndrome and electrophysiological study for risk stratification.

Hypertrophic cardiomyopathy (HCM) may be associated with considerable mortality in athletes. However, differentiating myocardial hypertrophy as a physiological adaptation of the heart to exercise can be a clinical challenge. In this context, nuclear magnetic resonance imaging has been shown to be a essential exam for diagnostic elucidation. The case report aimed to depict a young athlete with syncope and an initial investigation suggestive of HCM, which was excluded after deconditioning and serial MRI.